secwatch / observer
8-K filed November 25, 2025, 6:59 PM ET ticker LNAI CIK 0001527728
other material confidence high sentiment negative materiality 0.60

Lunai Bioworks raises $3.13M via private placement of stock and warrants

Lunai Bioworks Inc.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lunai Bioworks Inc. issued 3,133,333 shares of its common stock of common stock to an accredited investor for $1.00 per share.

Security
common stock
Shares
3,133,333 shares of its common stock
Purchaser
an accredited investor
Consideration
$1.00 per share
Exact text from the filing
On November 24, 2025, Lunai Bioworks Inc. (“Lunai” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an accredited investor (the “Investor”), pursuant to which the Company agreed to sell, and the Investor agreed to purchase, in a private placement, 3,133,333 shares of its common stock, par value $0.001 per share (the “Shares”), at a purchase price of $1.00 per share
View on SEC.gov
Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Lunai Bioworks Inc. issued 1,044,444 three-year warrants, executable after sixty (60) days of warrant to an accredited investor for included in aggregate gross proceeds of $3,133,333.

Security
warrant
Shares
1,044,444 three-year warrants, executable after sixty (60) days
Purchaser
an accredited investor
Consideration
included in aggregate gross proceeds of $3,133,333
Exact text from the filing
and 1,044,444 three-year warrants, executable after sixty (60) days (the “Warrants”) for aggregate gross proceeds of $3,133,333
View on SEC.gov

32 equity issuances filed in the last 30 days. Browse all equity issuances →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR
accession 0001731122-25-001597
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.